Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS

被引：0
|
作者：
Lingyun Wu
Xiao Li
Jiying Su
Qi He
Xi Zhang
Chunkang Chang
Quan Pu
机构：
[1] The Sixth Hospital Affiliated to Shanghai Jiaotong University,Department of Hematology
来源：
Journal of Cancer Research and Clinical Oncology | 2011年 / 137卷
关键词：
Myelodysplastic syndromes; Acute myeloid leukemia; Cytarabine; Homoharringtonine; Granulocyte colony-stimulating factor (G-CSF);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1563 / 1569
页数：6
相关论文
共 50 条
  • [21] Efficacy and toxicity of decitabine versus CHG regimen (low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor) in patients with higher risk myelodysplastic syndrome: a retrospective study
    Wu, Lingyun
    Li, Xiao
    Chang, Chunkang
    Xu, Feng
    He, Qi
    Wu, Dong
    Zhang, Zheng
    Su, Jiying
    Zhou, Liyu
    Song, Luxi
    Chao, Xiao
    Zhao, Youshan
    LEUKEMIA & LYMPHOMA, 2016, 57 (06) : 1367 - 1374
  • [22] Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia
    W. K. Hofmann
    G. Heil
    C. Zander
    S. Wiebe
    O. G. Ottmann
    L. Bergmann
    K. Hoeffken
    J. T. Fischer
    A. Knuth
    K. Kolbe
    H. J. Schmoll
    W. Langer
    M. Westerhausen
    C. B. Koelbel
    D. Hoelzer
    A. Ganser
    Annals of Hematology, 2004, 83 : 498 - 503
  • [23] Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia
    Hofmann, WK
    Heil, G
    Zander, C
    Wiebe, S
    Ottmann, OG
    Bergmann, L
    Hoeffken, K
    Fischer, JT
    Knuth, A
    Kolbe, K
    Schmoll, HJ
    Langer, W
    Westerhausen, M
    Koelbel, CB
    Hoelzer, D
    Ganser, A
    ANNALS OF HEMATOLOGY, 2004, 83 (08) : 498 - 503
  • [24] Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
    Anwar, Asma
    Halpern, Anna B.
    Othus, Megan
    Scott, Bart L.
    Hendrie, Paul C.
    Becker, Pamela S.
    Perdue, Andrea M.
    Smith, Heather A.
    Chen, Tara L.
    Buckley, Sarah A.
    Orlowski, Kaysey F.
    Powell, Morgan A.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2015, 126 (23)
  • [25] Second-Line Low-Dose Cytarabine after First-Line Treatment with 5-Azacitidine in Elderly Patients with AML or High-Risk MDS Ineligible for Intensive Chemotherapy. A Retrospective Single Center Analysis
    Jakob, Christian
    Gunther, Benjamin
    Dittberner, Katharina
    Boger, Leonard
    Bleienheuft, Philipp
    Breywisch, Frank
    Rothmann, Frank
    Peinert, Stefan
    Maschmeyer, Georg
    BLOOD, 2015, 126 (23)
  • [26] PROLONGED LOW-DOSE AZACITIDINE SCHEDULE IN HIGH-RISK MDS PATIENTS: LONG TERM EFFICACY AND RELATIONSHIP WITH MOLECULAR RESPONSE
    Clissa, C.
    Finelli, C.
    Follo, M.
    Stanzani, M.
    Papayannidis, C.
    Curti, A.
    Paolini, S.
    Mongiorgi, S.
    Manzoli, L.
    Martinelli, G.
    Cocco, L.
    Cavo, M.
    HAEMATOLOGICA, 2013, 98 : 309 - 309
  • [27] A maintenance therapy with differentiating agents and low-dose chemotherapy increases remission duration and survival in high risk AML and MDS patients.
    Ferrero, D
    Dellacasa, C
    Bonferroni, M
    Grasso, M
    Campa, E
    Giai, V
    Genuardi, M
    Boccadoro, M
    BLOOD, 2005, 106 (11) : 232B - 232B
  • [28] A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
    Halpern, Anna B.
    Othus, Megan
    Huebner, Emily M.
    Orlowski, Kaysey F.
    Scott, Bart L.
    Smith, Heather A.
    Becker, Pamela S.
    Percival, Mary-Elizabeth M.
    Hendrie, Paul C.
    Perdue, Andrea M.
    Chen, Tara L.
    Buckley, Sarah A.
    Erba, Harry P.
    Estey, Elihu H.
    Walter, Roland B.
    BLOOD, 2016, 128 (22)
  • [29] Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study
    Liu, Jing
    Liu, Xiaohong
    Jia, Jinsong
    Gong, Lizhong
    Lu, Shengye
    Wang, Jing
    Huang, Xiao-jun
    Jiang, Hao
    LEUKEMIA RESEARCH REPORTS, 2022, 18
  • [30] PHASE IB STUDY OF PF-04449913, A HEDGEHOG (HH) INHIBITOR, IN COMBINATION WITH LOW-DOSE CYTARABINE OR INTENSIVE CHEMOTHERAPY, IN ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Cortes, J.
    O'Connell, A.
    Shaik, M. N.
    Cesari, R.
    Abbattista, A.
    Woolfson, A.
    Pollyea, D.
    Savona, M.
    HAEMATOLOGICA, 2014, 99 : 33 - 33
12345